Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Palmoplantar Pustulosis Market Grown from 2024 to 2025?

In the past few years, the market size for palmoplantar pustulosis has experienced significant growth. Projections show its increase from $1.93 billion in 2024 to $2.10 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be linked to factors such as the escalating prevalence of autoimmune disorders, heightened awareness of rare skin conditions, an increase in healthcare spending, and the expanding adoption of telemedicine for dermatology.

What Growth Rate Is Anticipated for the Palmoplantar Pustulosis Market in the Coming Years?

In the upcoming years, the palmoplantar pustulosis market is projected to experience substantial growth, reaching $2.84 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. The anticipated expansion during this forecast period can be linked to the increased use of biologic therapies, escalating investments in dermatology research, a proliferating pipeline of innovative treatments, a surge in demand for personalized medicine, and a rising prevalence of chronic skin conditions. Progress in dermatology research, a shift towards biologics and immunomodulators, the application of artificial intelligence in dermatological diagnosis, the creation of advanced topical formulations, and the incorporation of machine learning in dermatological research are all key trends anticipated for this forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22090&type=smp

Who Are the Leading Companies in the Palmoplantar Pustulosis Market?

Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., C.H. Boehringer Sohn AG & Co. KG, Bausch Health Companies Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Swedish Orphan Biovitrum AB (Sobi), Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Taiho Pharmaceutical Co. Ltd., Kamari Pharma Ltd.

What Are the Key Drivers of the Palmoplantar Pustulosis Market?

The growth of the palmoplantar pustulosis market is expected to accelerate due to the rising prevalence of skin disorders. These disorders, impacting the structure, function, or look of the skin, are increasingly common due to environmental shifts, lifestyle practices, and genetic factors. Environmental conditions such as air contamination, severe weather patterns, and interaction with harmful substances can provoke skin irritation, resulting in issues like eczema or acne. Palmoplantar pustulosis is a long-running skin disease that significantly impacts the skin on the hand palms and foot soles, causing pustules, inflammation, and flaking, which can be managed with various therapies to enhance skin wellness and relieve distress. For example, the International Eczema Council, a US-based entity, reported in 2022 that approximately 223 million individuals suffered from atopic dermatitis, with 43 million of them aged between 1 and 4. Consequently, the escalating prevalence of skin disorders fuels the growth of the palmoplantar pustulosis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22090&type=smp

What Are the Key Market Segments in the Palmoplantar Pustulosis Industry?

The palmoplantar pustulosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatments, Systemic Treatments, Biologics, Phototherapy

2) By Application: Hospitals, Dermatology Clinics, Homecare Settings

3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospitals

Subsegments:

1) By Topical Treatments: Corticosteroids, Vitamin D Analogues, Calcineurin Inhibitors, Keratolytics

2) By Systemic Treatments: Retinoids, Immunosuppressants, Phosphodiesterase-4 (PDE4) Inhibitors, Corticosteroids

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors, Interleukin-12/23 (IL-12/23) Inhibitors

4) By Phototherapy: Narrowband UVB Therapy (NB-UVB), Psoralen plus Ultraviolet A (PUVA) Therapy, Excimer Laser Therapy, Targeted Phototherapy

What Are the Latest Trends in the Palmoplantar Pustulosis Market?

Key players in the palmoplantar pustulosis market are concentrating their efforts on the creation of innovative treatments, such as monoclonal antibodies that specifically target inflammation pathways, to enhance the health results of patients. Monoclonal antibodies (mAb) are identical antibodies created by a solitary clone of B cells that focus on a particular antigen for therapeutic or identifying purposes. For example, in August 2023, Japanese pharmaceutical firm Kyowa Kirin Co., Ltd., gained restrictive modification approval for LUMICEF for treating palmoplantar pustulosis in Japan. LUMICEF is a specific treatment designed to obstruct IL-17, providing immediate and prolonged relief from inflammatory disorders such as psoriasis and palmoplantar pustulosis. The primary goal of this therapy is to decrease inflammation and boost the life quality of patients affected by these persistent diseases.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/palmoplantar-pustulosis-global-market-report

What Are the Key Regional Markets in the Palmoplantar Pustulosis Industry?

North America was the largest region in the palmoplantar pustulosis market in 2024. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22090

This Report Delivers Insight On:

1. How big is the palmoplantar pustulosis market, and how is it changing globally?

2. Who are the major companies in the palmoplantar pustulosis market, and how are they performing?

3. What are the key opportunities and risks in the palmoplantar pustulosis market right now?

4. Which products or customer segments are growing the most in the palmoplantar pustulosis market?

5. What factors are helping or slowing down the growth of the palmoplantar pustulosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model